Chipping away at it. Will be interested to hear what a “modest...

Chipping away at it.

Will be interested to hear what a “modest reduction” in the required number of patients means.

Just hoping they don’t trim it too fine in the interests of completing the trial. Would be an awful shame to miss out on the target because there aren’t quite enough patients...

Fingers crossed.

Still can’t figure out why a company on the cusp of potentially transformative trial results has a MC of $32M. There are other companies out there who aren’t even starting phase 1 yet with the same market cap... I’m calling $132M before the end of the year.